Listen
MAVENCLAD (cladribine) - Multiple sclerosis (MS)
Opinions on drugs -
Posted on
Jun 12 2025
Reason for request
Reassessment at the request of the CT
Summary of opinion
Favourable opinion for maintenance of reimbursement in the treatment of adult patients with highly active relapsing multiple sclerosis (MS) defined by clinical or imaging (MRI) features.
Clinical Benefit
| Low |
The clinical benefit of MAVENCLAD (cladribine) remains low in the MA indication. |
Clinical Added Value
| Comments without ASMR value |
The Committee deems that the data provided in the context of this reassessment are not likely to modify the assessment of the clinical added value expressed in the previous opinion of 27 May 2020. |
Documents
English version
Contact Us
Évaluation des médicaments
